Treatment Goals and Disease Risks May Inform Treatment Selection in CML
Asciminib may be more tolerable than bosutinib in the treatment of those with chronic myeloid leukemia, according to Michael Deininger, MD.
ctDNA May Play Role in Large Cell Lymphoma Detection
Data from previous studies demonstrate that pretreatment levels of circulating tumor DNA may be prognostic in diffuse large B-cell lymphoma, according to Mark J. Roschewski, MD.
Cilta-Cel Yields PFS, Durable Responses in R/R Multiple Myeloma
Patients with multiple myeloma and enduring MRD-negativity are able to achieve the deepest responses with ciltacabtagene autoleucel, according to Yi Lin, MD, PhD.
Luspatercept Controls Anemia in Transfusion Dependent MDS Population
Luspatercept may provide clinical benefit regardless of subgroup and baseline mutation burden in transfusion dependent patients with myelodysplastic syndrome with anemia, according to Guillermo Garcia-Manero, MD.
Zotatifin Combo Yields Responses in Pretreated ER+ Metastatic Breast Cancer
Zotaifin plus abemaciclib and fulvestrant appears to produce no dose-limiting toxicities among patients with estrogen receptor–positive metastatic breast cancer in a phase 1/2 study.
Neoadjuvant Nivolumab/Chemo Improves Outcomes Vs Chemo in Resectable NSCLC
Patients who receive nivolumab plus chemotherapy for non–small cell lung cancer may experience sustained improvement in time to death or distant metastasis, according to an expert from McGill University Health Center.
PD-1/TIGIT Bispecific Has Preliminary Activity in Previously Treated NSCLC
Rilvegostomig appears to yield no dose-limiting toxicities among patients with advanced or metastatic PD-L1–positive non–small cell lung cancer in the phase 1/2 ARTEMIDE-01 study.
Vorasidenib Reduces Risk of Progression/Death in Low-Grade Glioma
In the study, 331 patients with IDH-mutated low-grade glioma were randomized to receive oral vorasidenib at 40 mg once daily or matched placebo in 28-day cycles.
Linvoseltamab Elicits Positive Efficacy in R/R Multiple Myeloma
Investigators report an increased objective response rate when linvoseltamab is given to patients with relapsed/refractory multiple myeloma.
Teclistamab/Talquetamab Appears Tolerable in R/R Multiple Myeloma
Results from the phase 1b RedirecTT-1 study show acceptable efficacy and safety when teclistamab plus talquetamab was given to patients with relapsed/refractory multiple myeloma.
Perioperative Pembrolizumab Improves Responses in Early-Stage NSCLC
For patients with early-stage non–small cell lung cancer, the addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab as a monotherapy results in a significant improvement in event-free survival and pathological response.
Rucaparib Improves rPFS Vs Physician’s Choice in BRCA+ mCRPC
Rucaparib yields improved efficacy compared with docetaxel plus androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer harboring BRCA mutations.
Sacituzumab Govitecan Yields Consistent Benefit in Platinum-Ineligible mUC
Data from the phase 2 TROPHY-U-01 trial support further evaluation of sacituzumab govitecan in patients with metastatic urothelial cancer following immune checkpoint inhibitor therapy, according to the lead investigator.
Transurethral Resection Plus Triplet Therapy Yields CRs in MIBC
Almost half of patients with muscle-invasive bladder cancer in a phase 2 trial had clinical complete responses following transurethral resection of bladder tumors plus nivolumab and chemotherapy.
Addition of Ibrutinib to CRT/ASCT Appears to Improve Outcomes for MCL
Treatment with induction and maintenance ibrutinib combined with chemoimmunotherapy and autologous stem cell transplant resulted in statistically significantly improved outcomes in a younger population with mantle cell lymphoma.
Second-Line Liso-Cel May Be Preferred Treatment Vs SOC in LBCL
Lisocabtagene maraleucel was found to have superior efficacy in the second-line over standard of care therapy for patients with relapsed/refractory large B-cell lymphoma.
Zanubrutinib Produces Superior Efficacy Over Ibrutinib in Relapsed/Refractory CLL/SLL
Results from the phase 3 ALPINE trial found improved progression-free survival and overall response rate when Zanubrutinib was given to patients with chronic lymphocytic leukemia or small lymphatic leukemia vs ibrutinib.
Heavily Pretreated Waldenström Macroglobulinemia Patients Benefit From Pirtobrutinib
The BTK inhibitor pirtobrutinib demonstrated high response rates in pretreated patients with Waldenström macroglobulinemia, according to recent data.
Elranatamab Produces Efficacy Response in Penta-or Triple-Class Refractory Multiple Myeloma
Patients with penta-or triple-class refractory multiple myeloma who have not received prior B-cell maturation antigen therapy saw an improved objective response rate when elranatamab was given.
PFS Improved with Sotorasib vs Docetaxel in KRAS G12C+ NSCLC
Findings from the phase 3 CodeBreaK 200 trial show improved progression-free survival with sotorasib vs docetaxel in previously treated KRAS G12C-mutant non–small cell lung cancer.
Efficacy Persists with Lenvatinib Plus Pembrolizumab Vs Sunitinib in Advanced Clear Cell RCC
Patients with advanced clear cell renal cell carcinoma given lenvatinib plus pembrolizumab had sustained overall survival and progression-free survival benefit vs sunitinib, according to updated results of the CLEAR trial.
Blood Test Shows Promise for Detection of Cancer
Results from a blood-based multi-cancer detection test potentially indicated the presence of cancer.
Neoadjuvant T-VEC Efficacy Consistent at 5 Years for Resectable Melanoma
Long-term results of a phase 2 study (NCT02211131) revealed consistent efficacy at 5 years with talimogene laherparepvec in stage IIIB to IVM1a melanoma.
Camrelizumab Plus Rivoceranib for Unresectable HCC Bests SOC Sorafenib
Results of a phase 3 study appear to indicate better progression-free and overall survival outcomes with camrelizumab and rivoceranib vs sorafenib in unresectable hepatocellular carcinoma.
TILs Show Better PFS vs Ipilimumab in Unresectable Melanoma
A randomized phase 3 trial presented at 2022 ESMO revealed better progression-free survival outcomes with tumor-infiltrating lymphocytes vs ipilimumab in stage IIIC/IV unresectable, treatment-refractory melanoma.
Activity of Rivoceranib in Adenoid Cystic Carcinoma Showcased at ASCO 2022
Treatment with the oral VEGFR2 inhibitor rivoceranib appears to induce responses in recurrent or metastatic adenoid cystic carcinoma.
Adjuvant Everolimus Yields RFS Benefit Over Placebo in Very High-Risk Renal Cell Carcinoma
Patients with very high-risk renal cell carcinoma experienced a notable relapse-free survival benefit vs placebo following treatment with everolimus.
Certain Luminal A Breast Cancers Can Forgo Radiotherapy After Breast Conserving Surgery
Radiotherapy can be avoided after surgery in certain patients with low-grade luminal A breast cancer who have low Ki67 expression and no positive lymph nodes, according to data from 2022 ASCO.
Trastuzumab Deruxtecan Doubles PFS in HER2-Low Metastatic Breast Cancer
The phase 3 DESTINY-Breast04 trial using fam-trastuzumab deruxtecan-nxki showed a reduction in the risk of disease recurrence or death for patients with HER2-low, hormone receptor–positive metastatic breast cancer.
CLDN18.2-Directed CAR T-cell Therapy Effective, Safe in Gastrointestinal Cancers
A Claudin18.2–specific CAR T-cell therapy has shown promise in the treatment of patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma whose disease expresses the marker.
2 Clarke Drive Cranbury, NJ 08512